Abstract
Systemic administration of voriconazole, a novel anti-fungal agent, is associated with adverse effects including visual disturbances and hepatic abnormalities. The purpose of this study was to improve the aqueous solubility of voriconazole using 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and to study the effect of addition of viscosity modifiers to these solutions. Statistical analysis was done by one-way analysis of variance followed by Dunnett's test. The phase solubility studies indicated that voriconazole solubility increased with increase in HP-β-CD concentration. Using a combination of chitosan 0.2%, BAK 0.01% and EDTA 0.01% in voriconazole- HP-β-CD based aqueous drops (1.5%, pH 7.0), a 3.9 times and 5.4 times higher Papp was obtained than with formulation without chitosan and control formulation (without chitosan and preservative), respectively. Thus, it could be concluded voriconazole aqueous drops formulated using HP-β-CD can be used topically for the treatment of fungal keratitis and the addition of chitosan to the voriconazole aqueous drops can produce significantly higher permeation.
Keywords: Chitosan, Fungal keratitis, HP-β-CD, Phase solubility, Transcorneal permeation, Voriconazole.
Current Drug Delivery
Title:Design and Evaluation of HP-β-CD Based Voriconazole Formulations for Ocular Drug Delivery
Volume: 11 Issue: 2
Author(s): Priyanka Pahuja, Heena Kashyap and Pravin Pawar
Affiliation:
Keywords: Chitosan, Fungal keratitis, HP-β-CD, Phase solubility, Transcorneal permeation, Voriconazole.
Abstract: Systemic administration of voriconazole, a novel anti-fungal agent, is associated with adverse effects including visual disturbances and hepatic abnormalities. The purpose of this study was to improve the aqueous solubility of voriconazole using 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and to study the effect of addition of viscosity modifiers to these solutions. Statistical analysis was done by one-way analysis of variance followed by Dunnett's test. The phase solubility studies indicated that voriconazole solubility increased with increase in HP-β-CD concentration. Using a combination of chitosan 0.2%, BAK 0.01% and EDTA 0.01% in voriconazole- HP-β-CD based aqueous drops (1.5%, pH 7.0), a 3.9 times and 5.4 times higher Papp was obtained than with formulation without chitosan and control formulation (without chitosan and preservative), respectively. Thus, it could be concluded voriconazole aqueous drops formulated using HP-β-CD can be used topically for the treatment of fungal keratitis and the addition of chitosan to the voriconazole aqueous drops can produce significantly higher permeation.
Export Options
About this article
Cite this article as:
Pahuja Priyanka, Kashyap Heena and Pawar Pravin, Design and Evaluation of HP-β-CD Based Voriconazole Formulations for Ocular Drug Delivery, Current Drug Delivery 2014; 11 (2) . https://dx.doi.org/10.2174/1567201810666131224105205
DOI https://dx.doi.org/10.2174/1567201810666131224105205 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beta-Blockers are Associated with Decreased In-Hospital Mortality and Stroke in Acute Decompensated Heart Failure: Findings from a Retrospective Analysis of a 22-Year Registry in the Middle East (1991-2013)
Current Vascular Pharmacology Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Methylene Blue not Contraindicated in Treating Hemodynamic Instability in Pediatric and Neonate Patients
Current Pediatric Reviews Veno-Arterial Extracorporeal Membrane Oxygenation in the Adult: A Bridge to the State of the Art
Current Cardiology Reviews Intensive Glucose Control in Diabetics with an Acute Myocardial Infarction Does not Improve Mortality and Increases Risk of Hypoglycemia-A Meta-Regression Analysis
Current Vascular Pharmacology MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews Pharmacophore Modeling for Antitargets
Current Topics in Medicinal Chemistry Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Beta-Adrenergic Antagonists: Indications and Potential Immunomodulatory Side Effects in the Critically Ill
Current Medicinal Chemistry Cardiac Telocytes
Current Stem Cell Research & Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Syncope: Review of Monitoring Modalities
Current Cardiology Reviews Determination of Torsade-Causing Potential of Drug Candidates Using One-Class Classification and Ensemble Modelling Approaches
Current Drug Safety Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design Torsadogenic Cardiotoxicity of Antipsychotic Drugs: a Structural Feature, Potentially Involved in the Interaction with Cardiac HERG Potassium Channels
Current Medicinal Chemistry Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy
Endocrine, Metabolic & Immune Disorders - Drug Targets